This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| AAV-P7/A1 | |
|---|---|
| Name | AAV-P7/A1 |
| Virus group | Unassigned |
| Realm | Varidnaviria |
| Family | Parvoviridae |
| Genus | Dependoparvovirus |
| Species | Adeno-associated virus |
AAV-P7/A1 AAV-P7/A1 is a synthetic adeno-associated virus (AAV) capsid variant engineered for enhanced gene delivery to specific tissues. It emerged from directed evolution and capsid shuffling strategies to improve transduction efficiency compared with natural serotypes, and has been evaluated in multiple preclinical platforms and translational studies.
AAV-P7/A1 derives from iterative capsid engineering campaigns that combined elements of natural serotypes and synthetic libraries to create a chimeric vector with altered tropism and stability. Developers reported improved performance in models where University of Pennsylvania and Massachusetts Institute of Technology teams previously advanced AAV technologies, building on foundational work from groups at Stanford University, Harvard University, University of Oxford, and industry partners such as Spark Therapeutics and uniQure. The variant has been discussed in contexts involving delivery to organs highlighted in studies from National Institutes of Health laboratories and collaborations with regulatory stakeholders like the U.S. Food and Drug Administration.
Design of AAV-P7/A1 employed directed evolution methods pioneered in labs at Salk Institute, Broad Institute, and California Institute of Technology, leveraging DNA shuffling, error-prone PCR, and capsid peptide display techniques whose origins trace to work at Cold Spring Harbor Laboratory and Rockefeller University. Screening platforms used animal models from facilities affiliated with Johns Hopkins University and vectoromics assays developed at University of California, Berkeley and ETH Zurich. Intellectual property considerations referenced filings by entities such as Biogen and collaborations resembling partnerships between Adverum Biotechnologies and academic inventors. Structural analyses invoked cryo-electron microscopy workflows refined at National Center for CryoEM and Tomography and computational prediction methods from DeepMind and labs like University of Cambridge.
AAV-P7/A1 exhibits a distinct receptor-binding profile relative to native serotypes, with altered interactions analogous to those studied for AAV9 and AAV8 in publications from University College London and University of Toronto. Preclinical tropism assessments referenced comparative transduction in models used by Children's Hospital of Philadelphia and Mayo Clinic, showing enhanced delivery to parenchymal cells in tissues investigated at Karolinska Institutet and Imperial College London. In vitro characterization employed cell lines originally characterized at Addgene repositories and primary cell systems consistent with methods from Cincinnati Children's Hospital Medical Center and Fred Hutchinson Cancer Center.
Production pipelines for AAV-P7/A1 followed scalable methods refined in process development groups at Genentech, Novartis, and contract development organizations like Lonza. Packaging used triple-plasmid transient transfection protocols popularized at University of California, San Francisco and helper systems analogous to those optimized by teams at University of Washington. Purification schemes referenced affinity chromatography approaches introduced by GE Healthcare and tangential flow filtration practices from Thermo Fisher Scientific. Quality control assays mirrored standards advocated by European Medicines Agency and analytical platforms established at Cytiva-affiliated labs.
Preclinical work with AAV-P7/A1 paralleled therapeutic programs targeting indications studied at Baylor College of Medicine and Vanderbilt University Medical Center, including gene replacement, optogenetics, and genome editing delivery strategies related to efforts at Editas Medicine and CRISPR Therapeutics. Animal efficacy models were performed in systems comparable to those used by The Jackson Laboratory and translational centers at Mount Sinai Health System, exploring neuromuscular, hepatic, and ocular targets featured in studies from Basel University Hospital and Moorfields Eye Hospital. Comparative performance assessments referenced benchmarks set by Luxturna development programs and investigational vectors advanced at Bluebird Bio-affiliated research.
Safety evaluations for AAV-P7/A1 addressed immunogenicity concerns characterized in seminal reports from University of Pennsylvania and NIH Clinical Center, examining neutralizing antibody responses and T cell reactivity similar to investigations by Cincinnati Children's Hospital and Massachusetts General Hospital. Biodistribution studies used imaging and PCR quantitation protocols established at Mayo Clinic and Scripps Research, with off-target profiling aligning with guidance from International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and pharmacovigilance practices used by Pfizer and Roche. Dose-ranging toxicology followed OECD and European Medicines Agency-oriented frameworks employed by academic safety cores.
Translational pathways for AAV-P7/A1 considered regulatory precedents set by approvals involving Spark Therapeutics and advisory interactions with the U.S. Food and Drug Administration and European Medicines Agency. Clinical development strategies mirrored trial designs undertaken at National Institutes of Health Clinical Center and large translational hubs such as Mayo Clinic and Cleveland Clinic, addressing manufacturing comparability issues similar to those resolved by sponsors including Biogen and Sanofi. Stakeholders emphasized informed consent frameworks modeled after multicenter studies coordinated by World Health Organization-affiliated networks and ethical oversight consistent with Declaration of Helsinki principles.
Category:Adeno-associated virus vectors